

Plasma Cell DNA Content and Proliferation,
Bone Marrow

## Overview

### **Useful For**

Establishing a diagnosis of a plasma cell proliferative disorder

Providing prognostic information for newly diagnosed multiple myeloma and other plasma cell proliferative disorders

Assessing response to therapy and detecting disease relapse and progression in treated plasma cell proliferative disorder patients

Determining plasma cell DNA content and proliferation

## **Additional Tests**

Test Id	Reporting Name	Available Separately	Always Performed
FCINT	Flow Cytometry Interp, 2-8	No, (Bill Only)	Yes
	Markers		

## **Testing Algorithm**

When this test is ordered, flow cytometry interpretation will always be performed at an additional charge.

For more information see:

- -Amyloidosis: Laboratory Approach to Diagnosis
- -Multiple Myeloma: Laboratory Screening

## **Special Instructions**

- Amyloidosis: Laboratory Approach to Diagnosis
- Multiple Myeloma: Laboratory Screening

## **Method Name**

Flow Cytometry/DNA Content/Cell Cycle Analysis

## **NY State Available**

Yes

## **Specimen**

## Specimen Type

**Bone Marrow** 



Plasma Cell DNA Content and Proliferation,
Bone Marrow

## **Ordering Guidance**

This test can be ordered at diagnosis or follow-up of a plasma cell neoplasm (plasma cell proliferative disorder).

If CSMRT / mSMART Plasma Cell Proliferative Disorder, Pre-Analysis Cell Sorting, Bone Marrow or MPCDS / mSMART, Plasma Cell Proliferative Disorder, FISH, Bone Marrow is desired to be performed at Mayo, order MSMRT / Mayo Algorithmic Approach for Stratification of Myeloma and Risk-Adapted Therapy Report, Bone Marrow.

The <u>Multiple Myeloma: Laboratory Screening</u> algorithm will allow plasma cell fluorescence in situ hybridization (FISH) testing to be added, based on this test's flow cytometry results.

## **Necessary Information**

- 1. Include patient's disease state (untreated, treated, monoclonal gammopathy of undetermined significance, stable).
- 2. Indicate if patient is on anti-CD38 therapy.

## **Specimen Required**

**Specimen Type:** Redirected bone marrow **Preferred:** Yellow top (ACD solution A or B)

Acceptable: Lavender top (EDTA) or green top (sodium heparin)

Specimen Volume: 4 mL

Specimen Stability Information: 3 days

#### **Forms**

If not ordering electronically, complete, print, and send a <u>Hematopathology/Cytogenetics Test Request</u> (T726) with the specimen.

### **Specimen Minimum Volume**

2 mL

## Reject Due To

Gross	Reject
hemolysis	
Fully clotted	Reject

## **Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
Bone Marrow	Ambient (preferred)		
	Refrigerated		

## **Clinical & Interpretive**

## **Clinical Information**

Plasma cell proliferative disorders are a group of plasma cell derived clonal hematologic neoplasms that exhibit a wide



Plasma Cell DNA Content and Proliferation,
Bone Marrow

range of biologic activity ranging from monoclonal gammopathy of uncertain significance (MGUS), a usually indolent disorder with a low rate of disease progression, to multiple myeloma (MM), a disease that is often aggressive with poor long-term survival. Detecting plasma cell clonality through demonstrating immunoglobulin (Ig) light chain restriction (ie, the presence of either predominately kappa or predominately lambda light chains), supplemented by the plasma cell immunophenotype and DNA index, is an important element in establishing the diagnosis.

It is important to correctly classify patients with plasma cell proliferative disorders as the various disease entities are treated differently. A number of factors are used for this classification including the proportions of clonal bone marrow plasma cells, the DNA index of the clonal plasma cells, and their proliferative activity. The plasma cell DNA index and proliferation assessment by flow cytometry are rapid and reliable. This information can be used to distinguish patients with overt active MM from less aggressive diseases such as MGUS and smoldering MM.

Furthermore, in combination with other laboratory data, the results of these studies can be used as a measure of disease aggressiveness in newly diagnosed MM and to determine therapeutic efficacy and detect disease relapse in treated MM patients.

The following algorithms are available:

- -Amyloidosis: Laboratory Approach to Diagnosis
- -Multiple Myeloma: Laboratory Screening

#### **Reference Values**

Plasma Cell Clonality:

Normal bone marrow

No monotypic clonal plasma cells detected

DNA Index:

Normal polytypic plasma cells

DNA index (G0/G1 cells): Diploid 0.95-1.05

### Interpretation

Plasma Cell Clonality:

Plasma cell populations with a kappa to lambda ratio of either greater than 3.9 or less than 0.5 will be considered either kappa or lambda immunoglobulin light chain restricted (monotypic), respectively. As, in rare instances, immunoglobulin light chain restricted plasma cell populations may be polyclonal at the genetic level, the term monotypic rather than monoclonal plasma cells will be used.

In addition to immunoglobulin light chain expression, other data collected will be used to supplement the detection of abnormal plasma cell populations. In plasma cells, CD19 expression is associated with the presence of benign, polytypic cell populations. Therefore, CD19 expression will be used as a secondary element in detecting clonal plasma cells. While loss of plasma cell CD45 expression is associated with neoplasia, CD45 is expressed by both normal and neoplastic plasma cells. Absence of plasma cell CD45 expression will be used as an aid in detecting abnormal plasma cells. In some plasma cell proliferative disorders there are both CD45-positive and CD45-negative subsets within the clonal cell population, therefore inclusion of antibodies to this antigen allows for more sensitive detection of both subtypes. In addition, as DNA content will be simultaneously assessed, the detection of plasma cell aneuploidy will also serve as a



Plasma Cell DNA Content and Proliferation,
Bone Marrow

tool for identifying abnormal plasma cell populations. These additional immunophenotypic tools for identifying abnormal plasma cells will increase the sensitivity of the method beyond examining light chain expression; particularly in biclonal plasma cell proliferative disorders in which there are both kappa and lambda immunoglobulin light chain expressing subsets.

#### Plasma Cell Proliferation:

The proportion of plasma cells in S-phase will be determined by measuring the proportion of cells with DNA content between the G0/G1 and G2/M peaks. In some instances, plasma cell proliferation will not be able to be determined by this method, including when there are fewer than 300 abnormal plasma cell events and when there are multiple aneuploid plasma cell populations. In newly diagnosed multiple myeloma, a plasma cell S-phase of greater than 2.0%, is associated with a more aggressive disease course; this value is published standard for identifying plasma cell neoplasms with a high proliferative rate, it will be noted in the report if the estimated S-phase exceeds this value.

### DNA Index:

Processed cells are stained with DAPI (4',6-diamidino-2-phenylindole) to determine the DNA index of the abnormal plasma cells. This will be determined by dividing the measured DNA content of the GO/G1 abnormal plasma cells by the DNA content of the normal GO/G1 plasma cells present. For this determination, normal plasma cells are the optimal control cell population due to similarities in nuclear and overall cell size. Plasma cells with a GO/G1 DNA content index of less than 0.95 will be considered hypodiploid (worst prognosis); those with a GO/G1 DNA content index of greater than 1.05 will be considered hyperdiploid (favorable prognosis). Plasma cells with a DNA index of 1.9 to 2.1 will be considered tetraploid (non-favorable prognosis) if a confirmatory G2/M population with a DNA index of 4 is identified. As noted above, since normal plasma cells are neither hyper- nor hypodiploid, DNA index will be used as a supplemental tool in detecting clonal plasma cells.

### Percent Polyclonal Plasma Cells in Total Plasma Cells:

It has been shown that higher percent polyclonal plasma cells in total plasma cells can mean longer progression-free survival, higher response rates, and lower frequency of high-risk cytogenetics abnormalities. Studies have also shown a higher incidence of polytypic plasma cells in monoclonal gammopathy of uncertain significance and smoldering myeloma in comparison to multiple myeloma.

## **Cautions**

In order to provide an adequate specimen, it is important that the marrow specimen be from a "redirect" marrow aspirate. The marrow needle should be redirected so the marrow can be aspirated from a previously unsampled site.

#### Clinical Reference

- 1. Aljama MA, Sidiqi MH, Lakshman A, et al. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Adv. 2018;2(22):3149-3154
- 2. Mellors PW, Binder M, Ketterling RP, et al. Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Adv. 2020;4(10):2236-2244
- 3. Palva B, Vidriales MB, Mateo G, et al. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. Blood. 2009;114(20):4369-4372
- 4. Sidana S, Jevremovic D, Ketterling RP, et al. Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method. Am J Hematol. 2019;94(4):424-430



Plasma Cell DNA Content and Proliferation,
Bone Marrow

5. Ghosh T, Gonsalves WI, Jevremovic D, et al. The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. Am J Hematol. 2017;92(9):E507-E512

6. Gonsalves WI, Buadi FK, Ailawadhi S, et al. Bone marrow transplant. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a mayo stratification of myeloma and risk-adapted therapy (msmart) consensus statement. 2019;54(3):353-367

#### **Performance**

## **Method Description**

Flow cytometric immunophenotyping of bone marrow is performed using the following antibodies; CD19, CD38, CD45, CD138, cytoplasmic kappa and lambda immunoglobulin, and DAPI (4',6-diamidino-2-phenylindole). Plasma cell clonality is detected through demonstrating CD38 and CD138 positivity along with immunoglobulin light chain restriction (ie, the presence of either predominately kappa or lambda immunoglobulin light chains) and abnormality of CD19 and/or CD45 expression. DNA index of clonal plasma cells and their proliferation activity is determined through staining of double-stranded DNA using DAPI. Plasma cells (monoclonal/monotypic and polyclonal/polytypic) are detected by immunoglobulin light chain restriction, surface immunophenotype, and DNA content. If present, the light chain expressed by the monotypic plasma cells is indicated. The percentage of clonal plasma cells estimated by flow cytometry is affected by specimen processing and antigen loss with specimen aging. Manual differential counting remains the accepted standard for determining the bone marrow plasma cell percentage. The percentage of monotypic plasma cells in S-phase of the cell cycle is determined by quantitative DNA analysis. The DNA index is a calculated value. The presence of more than 1 value indicates the presence of cell populations with differing DNA contents within the monotypic plasma cells. (Sidana S, Jevremovic D, Ketterling RP, et al. Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method. Am J Hematol. 2019;94(4):424-430)

## **PDF Report**

No

## Day(s) Performed

Preanalytical processing: Monday through Saturday

Results reported: Monday through Friday

## **Report Available**

1 to 4 days

### **Specimen Retention Time**

14 days

### **Performing Laboratory Location**

Rochester

## Fees & Codes



Plasma Cell DNA Content and Proliferation,
Bone Marrow

### Fees

- Authorized users can sign in to <u>Test Prices</u> for detailed fee information.
- Clients without access to Test Prices can contact <u>Customer Service</u> 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact <u>Customer Service</u>.

## **Test Classification**

This test was developed using an analyte specific reagent. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

## **CPT Code Information**

88182-Flow cytometry, cell cycle or DNA analysis

88184-Flow cytometry; first cell surface, cytoplasmic or nuclear marker

88185 x 5-Flow cytometry; additional cell surface, cytoplasmic or nuclear marker (each)

88187-Flow cytometry interpretation, 2 to 8 Markers (added as FCINT)

### **LOINC®** Information

Test ID	Test Order Name	Order LOINC® Value
PCPRO	Plasma Cell Proliferation, Marrow	93363-0

Result ID	Test Result Name	Result LOINC® Value
CK056	Monotypic Plasma Cells:	93362-2
CK057	Monotypic PC per Total Events	93021-4
CK058	Monotypic Plasma Cells S-phase	93361-4
CK059	Monotypic Plasma Cells DNA Index	93360-6
CK060	Monotypic Plasma Cells DNA Ploidy	93359-8
CK061	Polytypic PC per Total Events	93358-0
CK062	Polytypic PC per All Plasma Cells	93020-6
CK063	Final Diagnosis	50398-7